An interventional study of Exercise and radiotherapy in Lung Cancer, sponsored by Queen's University, Belfast. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Queen's University, Belfast · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Lung Neoplasms with a site in United Kingdom — 58 open to participants now, 83 under way, 24 of them phase 3. Lung Neoplasms · United Kingdom.
Among the 276 studies in Lung Neoplasms with a site in United Kingdom, this one is the 167th largest by planned enrollment of the 197 interventional ones that give a count, is one of 9 that started in 2026, is one of 46 with no phase, reaches primary completion later than 33 of the 82 other live ones, and was the 274th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →58 of the 276 studies in Lung Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Intuitive Surgical · Sites in United Kingdom, Germany, Switzerland
Ages 18+
Boehringer Ingelheim · Sites in United Kingdom, Australia, China and 5 more countries
Ages 18+
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
University of Edinburgh · Sites in United Kingdom, Norway
Ages 18+
TRIANA Biomedicines, Inc. · Sites in United Kingdom, United States, Australia and 1 more country
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 72 · Phase 3 75 · Phase 4 2
First in 1993; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 200 across the 197 interventional studies, 400 across the 71 observational. Of the 146 that completed or were terminated, 41 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 276 have an industry lead sponsor. The 10 most frequent:
Queen's University, Belfast is the lead sponsor of 117 studies on the registry; 14 are open to participants now.
Queen's University, Belfast has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
23 of the studies in Lung Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 23 to your calendar (.ics) → With an account.
Among the 276 studies in Lung Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to understand the feasibility of a co-designed, pre-radiotherapy exercise programme for people with stage I-III non-small cell lung cancer. This involves people with lung cancer engaging in 20 minutes exercises sessions performed within the radiotherapy department and immediately before each treatment at a personalised intensity.
The main questions it aims to answer are:
To understand the acceptability of the exercise programme through monitoring recruitment rates, attendance of the exercise sessions, and adherence to prescribed exercise intensities. Adverse events will also be monitored to understand programme safety.
Follow-up qualitative interviews will be conducted with participants, their family members, and health care professionals (HCP) to further explore the acceptability of the exercise programme.
In total, participants will be invited to perform up to twenty, supervised exercise sessions scheduled immediately before each treatment within the radiotherapy department. Each exercise session will be twenty minutes in duration and will be performed on a stationary exercise bike. Regarding exercise intensity, there are four levels which may be prescribed depending on people's exercise history, baseline exercise experience, and personal preference. Participants may progress or regress exercise intensity levels throughout the programme depending on their adherence and preference.
This is a sequential, mixed method feasibility study consisting of two phases:
Phase 1: Quantitative data collection (feasibility outcomes)
Phase 2: Qualitative data collection (semi-structured interviews)
The exercise programme used in this study was co-designed through a series of workshops and meetings involving individuals affected by lung cancer and healthcare professionals.
Eligible participants must be receiving a prescribed radiotherapy dose of either 55 Gy delivered in twenty fractions or 66Gy administered in 15 fractions, adminstered daily over a 3-4 week period. Accordingly, participants will be prescribed either 15 or 20 exercise sessions, performed once daily and scheduled in alignment with their radiotherapy treatment.
Exercise intensity is personalised and based on a submaximal exercise test conducted at the participant's baseline assessment. This test will be used to determine each participant's maximum heart rate, which will then be entered into the Karvonen formula (Karvonen et al., 1957) to calculate percentage heart rate reserve. This calculation will establish individual heart-rate ranges corresponding to light, moderate, and vigorous exercise intensities. Starting exercise intensity level (1-4) will be determined based on a baseline six-minute walking test, clinical frailty score, and participant preference.
The four levels of exercise intensity increase in difficulty, and incorporate various durations of light, moderate, or high intensity exercise, including:
All participants will wear a chest-strap heart-rate monitor during each exercise session to ensure they are exercising at the prescribed intensity. Session adherence will be defined as completion of at least 75% of the prescribed exercise duration (i.e. 15-minutes).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
People who are pregnant.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants within the experimental arm will participate in the co-designed, pre-radiotherapy exercise programme alongside treatment.
Other: Exercise · Radiation: radiotherapy
Participants will participate in up to twenty, supervised exercise sessions, performed within the radiotherapy department, immediately before each treatment. Each session has a 20 minute duration at one of four exercise intensity levels based on the participants baseline assessment results, and preferences.
Study participants will have been diagnosed with stage I-III NSCLC and prescribed radiotherapy administered as 55Gy in 20 fractions over 4 weeks or 60Gy in 15 fractions over 3 weeks as their primary treatment as per standard treatment pathways within the trust
Eligibility rates
The percentage of eligible participants identified and approached through participant screening
Time frame: Screening and enrolment
Recruitment rate
The total number of potential participants who were approached and agreed to participate as a percentage of the total number who were approached
Time frame: Screening and recruitment
Exercise programme attendance
The total number of attended sessions by the total number provided
Time frame: Weeks 4-8 (PReFACe exercise programme)
Adherence to the exercise programme
Monitoring the participants ability to complete the advised duration and intensity of exercise during each session (adherence is accepted if completed 75% of duration without intensity modification)
Time frame: Weeks 4-8 (PReFACe exercise programme)
Participant retention rates
The number of participants available to provide outcomes at the post-intervention assessment as a percentage of the total number recruited.
Time frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
Adverse event Common Terminology Criteria for Adverse Events (CTCAE) v5
Assess the tolerability and safety of the intervention, via recording of intervention-associated adverse events (AE). AEs will be graded according to CTCAE v.5 as: * Grade 1 = Mild * Grade 2 = Moderate * Grade 3 = Severe * Grade 4 = Life-threatening consequences * Grade 5 = Death related to AE
Time frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-items (EORTC QLQ-30)
EORTC QLQ-30 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer. The QLQ-C30 is composed of both multi-item scales and single-item measures, including: Five functional scales: * Physical * Role * Emotional * Cognitive * Social Three symptoms' scales: * Fatigue * Nausea and Vomiting * Pain A Global health Status (QoL) Six single items: * Dyspnoea * Insomnia * Appetite loss * Constipation * Diarrhoea * Financial difficulties All scales and single-item measures range in score from 0 to 100. High scale scores represent a higher response level, thus: * High scores for functional sales = high/healthy levels of functioning * High global health status = high QoL * High symptom scale/ single item scores = higher symptom burden
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)
EORTC QLQ-LC13 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer. The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing: * Pain * Coughing * Sore mouth * Dysphagia * Peripheral Neuropathy * Alopecia * Haemoptysis All single-item measures range in score from 0 to 100 with high scale scores representing a higher response level, thus: \- High symptom scale/ single item scores = higher symptom burden
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
Impact of exercise programmes effect on symptom burden: Pain likert Scale
Understanding the impact of the exercise programme on symptom burden on participants experience of pain using a 1-10 likert scale: * Scores 1-3 = Mild Pain * Scores 4-7 = Moderate pain * Scores 8-10 = Severe pain
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
Impact of exercise programmes effect on symptom burden: Fatigue likert Scale
Understanding the impact of the exercise programme on symptom burden on participants experience of fatigue using a 1-10 likert scale: * Scores 1-2 = No fatigue * Scores 3-4 = Minor fatigue * Scores 5-6 = Moderate fatigue * Scores 7-8 = Significant fatigue * Scores 9-10 = Extreme fatigue
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
Impact of exercise programmes effect on symptom burden: Modified Medical Research Council (MRC) dyspnoea scale
The modified MRC dyspnoea scale is a 5-point (0-4) questionnaire that assesses a patient's breathing difficulty, or dyspnoea, during activity. Higher scores correspond with more breathlessness etc: * grade 0 = breathless with strenuous exercise * grade 1 = short of breath when hurrying on level ground or walking up a slight hill * grade 2 = on level ground, I walk slower than people of my age because of breathlessness * grade 3 = I stop for breath after walking about 100 yards or after a few minutes on level ground * grade 4 = Too breathless to leave the house or I am breathless when dressing/undressing
Time frame: Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)
To assess the accessibility, acceptability and experience of the exercise programme through semi-structured qualitative interviews
Conduct of post-intervention, semi-structured, qualitative interviews with the following groups: 1. Phase 1 participants (who have completed the programme or withdrew from the programme) 2. Phase 1 participants nominated person (friend or family) 3. Healt Care Professionals (HCPs) involved/ exposed to the study A total of 15 participants (n=5 from each group) is deemed sufficient to achieve data saturation. Semi-structured interview schedules were pre-constructed for each group. Interview schedules consist of open-ended questions to explore the participants/experience of the exercise programme in their own words. No scales are used as a part of this outcome.
Time frame: Weeks 8-14 post-intervention follow-up period
Baseline compared to post-intervention changes in participant distress levels using the National Comprehensive Cancer Network (NCCN) Distress thermometer.
The distress thermometer is a valid, and accurate screening tool used to quickly monitor for patient's distress with advanced cancer. The thermometer uses a 0-10 scale to measure patient distress over the past week with 0 representing no distress and 10 representing extreme distress. The thermometer also features a "Problem List" (covering practical, family, emotional, spiritual, and physical issues) to pinpoint causes of distress for referral
Time frame: Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)
Change in baseline to post-intervention physical fitness: Six- minute walking test
A well-documented, validated and standardised sub-maximal fitness test measuring the distance a person can walk on a flat, solid surface in six minutes. Participants walk back and forth along a measured track to measure total distance covered in meters within six minutes. Greater distance covered (meters) indicate greater baseline fitness. Greater post-test distance covered (meters) than baseline scores indicate improvements in basic mobility. Reduced post-test distance covered (meters) than baseline scores indicate reductions in basic mobility.
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical fitness: 30-second sit-to-stand
A well-documented, validated, and standardised test to measure functional lower extremity strength. Participants perform as many sit-to-stand reps as they can within 30 seconds.
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical functioning: Rockwood Clinical Frailty Scale (CFS)
The Rockwood CFS is used as a valid assessment tool for screening frailty in older adults. This is a 1-9 scale, with higher scores indicating greater frailty: 1. Very fit 2. Well 3. Managing well 4. Vulnerable 5. Mildly frail 6. Moderately frail 7. Severely frail 8. Very severely frail 9- Terminally ill
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical activity: The International Physical Activity Questionnaire - Short Form (IPAQ-SF)
The IPAQ-SF will be used to explore the influence of the pre-radiotherapy exercise programme on the participant's weekly physical activity levels pre- and post-study. Based on results, physical activity levels based on scores can be calculated as: 1. Inactive 2. Minimally active 3. HEPA active (health enhancing physical activity; a high active category)
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical activity: Huffman Exercise Satisfactions Scale
The Huffman Exercise Satisfaction Scale was developed with stakeholders as a novel approach to measure older adults (aged ≥55 years) satisfaction with their physical activity levels. There questionnaire measures two scales: 1. A Physical activity enjoyment scale, consisting of 8 multiple choice questions. Responses are allocated a range from 1 to 7 with higher values indicate higher levels of enjoyment of physical activity 2. Satisfaction measure, consists of 4, multiple choice questions. Responses to the satisfaction items range from 1 to 7, with higher values indicating higher levels of satisfaction with physical activity. Mean scores are taken from each scale to total participants exercise enjoyment and satisfaction.
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Currently under review with supervisory team
Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 7 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.